Related Experiment Video
Updated: Jul 19, 2025
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
An unbiased seed-based RNAi selection screen identifies small RNAs that inhibit androgen signaling and prostate
Joshua M Corbin1,2, Constantin Georgescu3, Lin Wang4
1Stephenson Cancer Center, 800 NE 10th Street, Oklahoma City, OK 73104, USA.
Abstract:
Blocking androgen receptor signaling is the mainstay of therapy for advanced prostate cancer (PCa). However, acquired resistance to single agents targeting this pathway results in the development of lethal castration-resistant PCa. Combination therapy approaches represent a promising strategy for the treatment of advanced disease. Here, we explore a therapeutic strategy for PCa based on the ability of shRNAs/siRNAs to function essentially as miRNAs and, via seed sequence complementarity, induce RNA interference of numerous targets simultaneously. We developed a library that contained shRNAs with all possible seed sequence combinations to identify those ones that most potently reduce cell growth and viability when expressed in PCa cells. Validation of some of these RNAi sequences indicated that the toxic effect is associated with seed sequence complementarity to the 3' UTR of AR coregulatory and essential genes. In fact, expression of siRNAs containing the identified toxic seed sequences led to global inhibition of AR-mediated gene expression and reduced expression of cell-cycle genes. When tested in mice, the toxic shRNAs also inhibited castration-resistant PCa and exhibited therapeutic efficacy in pre-established tumors. Our findings highlight RNAi of androgen signaling networks as a promising therapeutic strategy for PCa.
Insights
Researchers developed a novel RNA interference (RNAi) therapy for advanced prostate cancer (PCa). This approach targets androgen receptor signaling, showing efficacy in preclinical models of castration-resistant PCa.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Advanced prostate cancer (PCa) therapy relies on blocking androgen receptor (AR) signaling.
- Acquired resistance to AR-targeting agents leads to lethal castration-resistant PCa (CRPC).
- Combination therapies offer a promising strategy for advanced PCa treatment.
Purpose of the Study:
- To explore a novel RNA interference (RNAi) therapeutic strategy for PCa.
- To identify shRNA sequences that induce potent cell growth inhibition via miRNA-like seed complementarity.
- To evaluate the efficacy of identified RNAi sequences in preclinical PCa models.
Main Methods:
- Developed a library of shRNAs with diverse seed sequences for PCa cells.
- Validated RNAi sequences targeting AR coregulatory and essential genes.
- Assessed therapeutic efficacy of toxic shRNAs in mouse models of castration-resistant PCa.
Main Results:
- Identified shRNAs that reduce PCa cell growth and viability.
- Demonstrated that toxic effects correlate with seed sequence complementarity to AR pathway genes.
- Observed global inhibition of AR-mediated gene expression and reduced cell-cycle gene expression.
- Showed therapeutic efficacy of toxic shRNAs in inhibiting castration-resistant PCa and pre-established tumors in mice.
Conclusions:
- RNAi targeting androgen signaling networks represents a promising therapeutic strategy for PCa.
- This approach effectively inhibits castration-resistant prostate cancer progression.
- Identified toxic seed sequences offer a novel mechanism for disrupting AR signaling in PCa.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:30Small interfering RNAs (siRNA)